Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Angio-Seal

This article was originally published in The Gray Sheet

Executive Summary

Hemostatic puncture closure system includes sizes 6F and 8F following FDA market go-ahead for the smaller version, granted to marketing partner St. Jude Medical and announced March 9. The 6F device, which addresses the market for punctures created during diagnostic catheterization procedures, gives St. Jude and Kensey Nash access to approximately 70% of the 6.5 mil. procedures performed through a 6F or smaller puncture in the femoral artery, Kensey Nash notes. An immediate launch of the Kensey Nash-made device through St. Jude's Daig division is anticipated
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel